Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00691405 · ClinicalTrials.gov registry record · Phase 2
A Dose Ranging Study of Arformoterol Given Once Daily Compared to Arformoterol Given Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
A Phase 2 study, sponsored by Sumitomo Pharma America.
- Completed
- Registry status
- Phase 2
- Development phase
- 215
- Enrollment target
NCT00691405 is a Phase 2 study that has completed, run by Sumitomo Pharma America. The registered enrollment target is 215 participants.
The verdict
NCT00691405, a Phase 2 study, has completed, sponsored by Sumitomo Pharma America.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 215 participants
- Enrollment target
Study Summary
A dose ranging study to evaluate the safety, tolerability and efficacy of arformoterol (given once or twice a day) in subjects with COPD.
Interventions
- DRUG Placebo
- DRUG Arformoterol tartrate inhalation solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 215 participants |
| Start Date | 2003-10 |
| Est. Completion | 2004-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00691405
The ClinicalTrials.gov registry entry for NCT00691405 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 215 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sumitomo Pharma America, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00691405 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00691405 about?
NCT00691405 is a clinical study titled "A Dose Ranging Study of Arformoterol Given Once Daily Compared to Arformoterol Given Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)". A dose ranging study to evaluate the safety, tolerability and efficacy of arformoterol (given once or twice a day) in subjects with COPD.
What is the current status of trial NCT00691405?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 215 participants. The study started on 2003-10. Estimated completion is 2004-05.
What interventions are being tested in trial NCT00691405?
The interventions under investigation include: Placebo (DRUG), Arformoterol tartrate inhalation solution (DRUG).
Who is sponsoring clinical trial NCT00691405?
This trial is sponsored by Sumitomo Pharma America, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.